DNA Repair in Patients With Stable Angina.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

172 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-05

Study Completion Date

2024-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Markers of DNA damage and repair are present in both atherosclerotic plaques and peripheral blood mononuclear cells of patients with coronary artery disease. A positive correlation has been observed between the level of DNA damage and the severity of atherosclerotic lesions, as well as atherogenic risk factors such as smoking, hypertension and hyperlipidaemia. A number of in-vitro studies have implicated defective DNA repair in the development and progression of atherosclerotic lesions. In mouse models of atherosclerosis, the DNA repair signalling cascade has been shown to be amenable to pharmacological intervention and overexpression of specific repair proteins attenuate the development of atherosclerotic plaques. However, data regarding the role of DNA repair in the pathogenesis of atherosclerosis in humans are lacking. We have preliminary data indicating reduced DNA repair activity in patients with stable angina. This study will determine the molecular basis and the biological consequences of this observation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Association Between Telomere Length and Risk of Acute Coronary Syndrome

NCT02775279

Acute Coronary Syndrome

COMPLETED

Circulating Non-coding RNAs and Cardiovascular Outcomes in Patients With Dyslipidemia and Atherosclerosis

NCT03279770

Cardiovascular Diseases

UNKNOWN

Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction

NCT04998227

Acute Coronary Syndrome Acute Coronary Syndrome With Renal Dysfunction

RECRUITING

Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome

NCT00167024

Prostate Cancer

UNKNOWN

Association Between Telomere Length and Cardiac Dysfunction

NCT04409379

Cardiac Toxicity Acute Leukemia Childhood Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Coronary Arteriosclerosis DNA Damage DNA Repair Abnormality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient Arm.

Consecutive patients undergoing elective percutaneous coronary intervention (PCI) or isolated coronary artery bypass grafting (CABG) for symptomatic stable angina (SA) despite optimal medical therapy at the University Hospital Southampton NHS Foundation Trust will be prospectively enrolled (n=86).

No interventions administered. 40ml of whole blood in EDTA vials to be taken for cellular separation and analysis.

No interventions assigned to this group

Age and gender matched controls

Age and gender-matched patients being investigated for chest pain with unobstructed coronary arteries, defined as coronary stenosis ≤ 30% in any major epicardial vessel on CT or invasive coronary angiography, will also be recruited as controls (n=86).

40ml of whole blood in EDTA vials to be taken for cellular separation and analysis.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Ability to provide written informed consent

Exclusion Criteria

* Age ≥ 80 years
* Inability to provide written informed consent
* Presentation with an acute coronary syndrome
* Severe valvular heart disease
* Hypertrophic cardiomyopathy
* Left ventricular ejection fraction ≤ 35%
* Prior coronary revascularisation (surgical or percutaneous)
* Diabetes Mellitus
* Clinical evidence of peripheral vascular disease
* Prior history of cerebrovascular disease
* Malignancy
* Active inflammatory disorders (e.g. rheumatoid arthritis/connective tissue disorder)
* Renal impairment eGFR \<60ml/min/1.73m2
* Anaemia (Hb \<100g/dL)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes